Pacira BioSciences (PCRX)
(Real Time Quote from BATS)
$15.05 USD
+0.36 (2.45%)
Updated Sep 20, 2024 10:09 AM ET
3-Hold of 5 3
A Value B Growth F Momentum A VGM
Brokerage Reports
0 items in cart
Pacira BioSciences, Inc. [PCRX]
Reports for Purchase
Showing records 421 - 440 ( 729 total )
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
We are initiating coverage with a Buy rating and an $43 target price
Provider: H.C. Wainwright & Co., Inc.
Analyst: DAVIS C
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Symphony Health November EXPAREL Sales Estimate Accelerated Over October and Is About -3% of Consensus; Reiterate OUTPERFORM and $89 Price Target.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
December and Full Year 2017 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
October EXPAREL and Comparators Sales Decreased Month-Over-Month; Reiterate OUTPERFORM and $89 Price Target.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
After the Election: Impact to Biotech of a Trump Presidency
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
November and Full Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Near-Term Headwinds Persist but Reacceleration of EXPAREL Sales Expected as New Initiatives Take Hold; Reiterate OUTPERFORM but Reducing PT to $89
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of Oct 31
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of Oct 24
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Q3 Preview: Symphony Health Q3 EXPAREL Estimate Is About 4% Below Consensus and We Reduced Our Estimates; Reiterate OUTPERFORM but Reducing PT to $93
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L